Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ACXP
Acurx Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close
Jul 27, 2026 2:25:38 PM EDT
1.46USD+2.465%(+0.04)51,045
1.39Bid   1.61Ask   0.22Spread
Pre-market
Jul 27, 2026 9:29:30 AM EDT
1.41USD-0.704%(-0.01)2,000
After-hours
Jul 27, 2026 4:00:30 PM EDT
1.43USD-1.718%(-0.03)473
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 6, 2021
08:06AM EST  CORRECTION: NGM Biopharmaceuticals Ticker Is 'NGM'   Benzinga
08:06AM EST  Acurx Announces First Patient Enrolled In Phase 2b Clinical Trial Of Its Lead Antibiotic For Treatment Of Clostridioides Difficile Infection   Benzinga
08:05AM EST  NGM Bio Announces Clinical Trial Collaboration With Merck Related To Ongoing Phase 1/2 Trial Of NGM707 In Combination With Merck's KEYTRUDA   Benzinga
08:03AM EST  Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead   PR Newswire
Nov 30, 2021
04:03PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021   Benzinga
Nov 29, 2021
08:34AM EST  Maxim Group Initiates Coverage On Acurx Pharmaceuticals with Buy Rating, Announces Price Target of $12   Benzinga
Nov 15, 2021
11:07AM EST  Earnings Scheduled For November 15, 2021   Benzinga
Nov 12, 2021
06:01PM EST  Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides   PR Newswire
Nov 8, 2021
08:07AM EST  Acurx Highlights Nov. 5 Presentation Of New Microbiome Data From Its Phase 2a Clinical Trial Of Ibezapolstat At 9th International C. diff. Conference   Benzinga
08:03AM EST  Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of   PR Newswire
Nov 5, 2021
09:43AM EDT  The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill   Benzinga
Nov 1, 2021
08:09AM EDT  Acurx Announces New Microbiome Data From Its Phase 2a Clinical Trial Of Ibezapolstat For C. Difficile Infection   RTTNews
08:03AM EDT  Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of   PR Newswire
08:03AM EDT  Acurx Pharma to Present New Data from its Phase 2a Trial of Ibezapostat on November 5th   Benzinga
Oct 27, 2021
08:03AM EDT  Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on   PR Newswire
Oct 4, 2021
11:25AM EDT  Acurx Pharmaceuticals, Inc. (ACXP) shares are sliding more than 11 percent on Monday morning trade, in search of new support.   RTTNews
09:03AM EDT  Acurx Pharma Reports Ibezapolstat Microbiome Data From Phase 2a Trial: 'trial demonstrated 100% clinical cure and sustained clinical cure,' Showed 'Favorable microbiome changes included overgrowth'   Benzinga
09:01AM EDT  Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at   PR Newswire
Sep 30, 2021
08:02AM EDT  Antimicrobials Working Group Highlights Member Company Participation at IDWeek   PR Newswire
Sep 29, 2021
08:01AM EDT  Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma   PR Newswire
Sep 27, 2021
08:27AM EDT  Acurx Announces New Microbiome Data From Phase 2a Trial Of Ibezapolstat For CDI; Advancing To Phase 2b   RTTNews
08:01AM EDT  Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference   PR Newswire
08:01AM EDT  Acurx To Give Poster Presentation Of Microbiome Data From Its Phase 2a Clinical Trial Of Ibezapolstat At IDWeek 2021 Conference Sept. 29-Oct. 3   Benzinga
Sep 2, 2021
08:13AM EDT  Acurx Pharmaceuticals To Join The Russell Microcap Index   Benzinga
Aug 31, 2021
08:01AM EDT  Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global   PR Newswire
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
07:00AM EDT  EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 14th Emerging Growth Conference.   GlobeNewswire Inc
Aug 16, 2021
04:26PM EDT  Acurx Pharmaceuticals Q2 EPS $(0.57) Down From $(0.15) YoY   Benzinga
Aug 12, 2021
08:01AM EDT  Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August   PR Newswire
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
08:02AM EDT  Acurx Pharmaceuticals Joins the Antimicrobials Working Group   PR Newswire
Aug 2, 2021
08:05AM EDT  Acurx Pharma Wins $500K Grant To Leiden University Medical Center   Benzinga
Jul 28, 2021
08:01AM EDT  Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on   PR Newswire
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 7, 2021
09:11AM EDT  Acurx Announces Filing Of Provisional Patent Application For Ibezapolstat To Treat CDI   RTTNews
09:06AM EDT  Acurx Announces Filing Of Provisional Patent Application For Ibezapolstat To Treat CDI While Reducing Recurrence Of Infection   Benzinga
09:03AM EDT  Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome   PR Newswire
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jul 6, 2021
04:45PM EDT  Robert J. DeLuccia Reports In 13D Filing A 13% Stake In Acurx Pharmaceuticals   Benzinga
Jul 1, 2021
08:03AM EDT  UPDATE: Acurx Says 'Using samples from Phase 1 healthy volunteers and a novel OMICS analysis approach, ibezapolstat differed favorably from vancomycin in microbiota abundance including a marked increase in Proteobacteria and Fusobacterium, concentration'   Benzinga
08:02AM EDT  Acurx Highlights New Ibezapolstat Data On Anti-Recurrence Mechanisms In Clostridiodes Difficile Infection At Int'l. Conference   Benzinga
08:01AM EDT  Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at   PR Newswire
Jun 29, 2021
04:01PM EDT  common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES   PR Newswire
Jun 28, 2021
10:08AM EDT  Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook   Benzinga
Jun 25, 2021
10:20AM EDT  Acurx Pharmaceuticals Shares Open For Trade At $5.95; IPO Priced At $6/Share   Benzinga
09:14AM EDT  Acurx Pharmaceuticals Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $6/Share   Benzinga
08:05AM EDT  Acurx Announces Pricing Of $15 Mln IPO Of Common Stock   RTTNews
08:02AM EDT  Acurx Pharma Prices 2.5M Share Offering At $6/Share   Benzinga
08:01AM EDT  Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC